Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  KV Pharmaceutical Co    

KV PHARMACEUTICAL CO

SummaryNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

K-V Pharmaceutical Company : K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/10/2012 | 04:06pm EDT

Contact Information: Brainerd Communicators, Inc.

Tony Herrling
212-739-6738
herrling@braincomm.com

Brad Edwards
212-986-6667
edwards@braincomm.com

K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court

Follows Agreement Between the Company and Its Senior Note Holders Regarding Cash Collateral

St. Louis, MO, August 8, 2012 - K-V Pharmaceutical Company ("K-V" or "the Company") today announced that all "First Day" motions presented to the U.S. Bankruptcy Court on August 7, 2012 that were included as part of the Company's initial filings in its voluntary reorganization cases were approved on either an interim or final basis by the U. S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding.

"Together with the Court's prior approval of our First Day motions, this authorization of the use of cash collateral is another important step forward, further ensuring that K-V is able to continue operations and focus on the restructuring process," said Greg Divis, President and CEO of K-V Pharmaceutical. "Meanwhile, reaching agreement regarding this matter with our Senior Noteholders sets the stage for continued cooperation toward the development of a plan of restructuring under which K-V will be able to emerge from chapter 11 as a stable and competitive company," Divis concluded.

K-V and certain of its affiliates commenced cases to reorganize under chapter 11 of the U.S. Bankruptcy Code on August 4, 2012. The chapter 11 cases are being jointly administered under case number 12-13346.

As a further step along the path of its restructuring, the Office of the United States Trustee will hold a meeting to form an Official Committee of Unsecured Creditors on August 13, 2013. Final hearings on the First Day motions, certain other motions as well as a final hearing on the use of cash collateral are scheduled for August 23, 2012.

Updates and additional information can be found at the Company's website www.kvph.com. In addition, the Company's Claims Administrator, Epiq Bankruptcy Solutions, Inc., maintains a web-based resource where documents from the chapter 11 cases, including the Company's Petitions, can be found, http://dm.epiq11.com/KVD.

About K-V Pharmaceutical Company

K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare. As such, we are committed to advancing the health of women across all the stages of their lives.

For further information about K-V Pharmaceutical Company, please visit the Company's corporate website at www.kvph.comm.

Cautionary Note Regarding Forward-looking Statements

This release contains various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (the "PSLRA") and which may be based on or include assumptions concerning our operations, future results and prospects. Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could," "potential" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including, without limitation, statements about product launches, governmental and regulatory actions and proceedings, market position, revenues, expenditures and the impact of the recall and suspension of shipments on revenues, adjustments to the financial statements, the filing of amended SEC filings and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA's "safe harbor" provisions, we provide the following cautionary statements identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions. Such factors include (but are not limited to):
(1) the ability of the Company and its subsidiaries to continue as a going concern;
(2) the ability of the Company and its subsidiaries to obtain Bankruptcy Court approval with respect to motions in the Chapter 11 cases;
(3) the ability of the Company and its subsidiaries to prosecute, develop and consummate one or more plans of reorganization with respect to the Chapter 11 cases;
(4) the effects of the bankruptcy filing on the Company and its subsidiaries and the interests of various creditors, equity holders and other constituents;
(5) the effects of rulings of the Bankruptcy Court in the Chapter 11 cases and the outcome of the cases in general;
(6) the length of time the Company and its subsidiaries will operate under the Chapter 11 cases;
(7) risks associated with third-party motions in the Chapter 11 cases, which may interfere with the ability of the Company and its subsidiaries to develop one or more plans of reorganization and consummate such plans once they are developed;
(8) the potential adverse effects of the Chapter 11 proceedings on the Company's liquidity or results of operations;
(9) the ability to execute the Company's business and restructuring plans;
(10) increased legal costs related to the Company's bankruptcy filing and other litigation;
(11) that its Class A Common Stock and Class B Common Stock will be, or will continue to be, traded on the OTCQB Marketplace and whether sufficient volumes and liquidity will develop; and
(12) the ability of the Company and its subsidiaries to maintain contracts that are critical to their operation, including to obtain and maintain normal terms with their vendors, customers and service providers and to retain key executives, managers and employees.

This discussion is not exhaustive, but is designed to highlight important factors that may impact our forward-looking statements.

Because the factors referred to above, as well as the statements included in Part I, Item 1A-"Risk Factors," of our Annual Report on Form 10-K for the fiscal year ended March 31, 2012 and under the heading "Risk Factors" in our Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 31, 2012, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. All forward-looking statements attributable to us are expressly qualified in their entirety by the cautionary statements in this "Cautionary Note Regarding Forward-Looking Statements" and the risk factors that are included under Part I, Item 1A of the our Annual Report on Form 10-K for the fiscal year ended March 31, 2012 and under the heading "Risk Factors" in our Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 31, 2012. Further, any forward-looking statement speaks only as of the date on which it is made and we are under no obligation to update any of the forward-looking statements after the date of this release. New factors emerge from time to time, and it is not possible for us to predict which factors will arise, when they will arise and/or their effects. In addition, we cannot assess the impact of each factor on our future business or financial condition or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.



distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KV PHARMACEUTICAL CO
2013WEEK AHEAD : Disney's Earnings on Tap; Media Companies to Report
DJ
2013WEEK AHEAD : Earnings Reporting to Continue with Tech, Energy
DJ
2013KV PHARMACEUTICAL CO : Ther-Rx Corporation and Perrigo Company Announce the Avai..
PU
2013KV PHARMACEUTICAL CO : K-V Pharmaceutical Receives Court Approval of Hologic Set..
PU
2012KV PHARMACEUTICAL CO : K-V Pharmaceutical Secures Commitment for $85 Million Loa..
PU
2012K-V Pharma Protests Hologic Bid to Reacquire Drug
DJ
2012Correction to U.S. Equities Week Ahead Story
DJ
2012US EQUITIES WEEK AHEAD : Luxury Retail Earnings; August Same-Store Sales
DJ
2012Cohen's SAC Capital Named to K-V Creditor Committee
DJ
2012K-V PHARMACEUTICAL COMPANY : K-V Pharmaceutical Use of Cash Collateral Approved ..
PU
More news
Chart KV PHARMACEUTICAL CO
Duration : Period :
KV Pharmaceutical Co Technical Analysis Chart | MarketScreener
Full-screen chart
Sector and Competitors